Nadolol (tablet): Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 39: | Line 39: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Nadolol is a non-selective [[beta blocker]]; that is, it non-selectively blocks both [[beta-1 receptor|beta-1]] and [[beta-2 receptor]]s. It has a preference for beta-1 receptors, which are predominantly located in the [[heart]], thereby inhibiting the effects of [[catecholamine]]s and causing a decrease in [[heart rate]] and [[blood pressure]]. Its inhibition of beta-2 receptors, which are mainly located in the [[bronchus|bronchial]] [[smooth muscle]] of the [[airway]]s, leads to airway constriction similar to that seen in [[asthma]]. Inhibition of beta-1 receptors in the [[juxtaglomerular apparatus]] of the [[kidney]] inhibits the [[renin-angiotensin system]], causing a decrease in [[vasoconstriction]] and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure. | Nadolol is a non-selective [[beta blocker]]; that is, it non-selectively blocks both [[beta-1 receptor|beta-1]] and [[beta-2 receptor]]s. It has a preference for beta-1 receptors, which are predominantly located in the [[heart]], thereby inhibiting the effects of [[catecholamine]]s and causing a decrease in [[heart rate]] and [[blood pressure]]. Its inhibition of beta-2 receptors, which are mainly located in the [[bronchus|bronchial]] [[smooth muscle]] of the [[airway]]s, leads to airway constriction similar to that seen in [[asthma]]. Inhibition of beta-1 receptors in the [[juxtaglomerular apparatus]] of the [[kidney]] inhibits the [[renin-angiotensin system]], causing a decrease in [[vasoconstriction]] and a decrease in water retention. Nadolol's inhibition of [[beta-1]] receptors in the heart and kidney leads to its effects on lowering blood pressure. | ||
The drug impairs [[atrioventricular node|AV node]] conduction and decreases [[sinoatrial node|sinus]] rate. | The drug impairs [[atrioventricular node|AV node]] conduction and decreases [[sinoatrial node|sinus]] rate. | ||
Revision as of 02:46, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information about Nadolol, click here.
Synonyms / Brand Names: CORGARD®
Overview
Nadolol (Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol) is a non-selective beta blocker used in the treatment of high blood pressure and chest pain (its only FDA approved uses).[1] Additionally, it is often prescribed in the treatment of migraine headaches, adult attention deficit hyperactivity disorder,[2] essential tremor, and Parkinson's disease.[3][4][5]
Category
Beta blockers
FDA Package Insert
CORGARD (nadolol) tablet
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Nadolol is a non-selective beta blocker; that is, it non-selectively blocks both beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and causing a decrease in heart rate and blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma. Inhibition of beta-1 receptors in the juxtaglomerular apparatus of the kidney inhibits the renin-angiotensin system, causing a decrease in vasoconstriction and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney leads to its effects on lowering blood pressure.
The drug impairs AV node conduction and decreases sinus rate.
Nadolol may also increase plasma triglycerides and decrease HDL-cholesterol levels.
References
- ↑ Drug Facts And Comparisons (2011 ed.). 77 Westport Plaza, Suite 450, St. Louis, Missouri: Wolters Kluwer Health. pp. (4)775.
- ↑ http://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AGG0LAgDus&sig=ctayeAWE3Nkoki-_EhfeLJ2uR1I&hl=en&sa=X&ei=9a40UvX7G8nDqQHSm4HQCg&ved=0CHYQ6AEwCDgK#v=onepage&q=Nadolol%20for%20ADHD&f=true
- ↑ http://books.google.com/books?id=EkyTTvjNRZAC&pg=PA669&lpg=PA669&dq=Nadolol+for+ADHD&source=bl&ots=AGG0LAgDus&sig=ctayeAWE3Nkoki-_EhfeLJ2uR1I&hl=en&sa=X&ei=9a40UvX7G8nDqQHSm4HQCg&ved=0CHYQ6AEwCDgK#v=onepage&q=Nadolol%20for%20ADHD&f=true
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/6348587
- ↑ http://www.drugs.com/dosage/nadolol.html#Usual_Adult_Dose_for_Parkinsonian_Tremor